<?xml version='1.0' encoding='utf-8'?>
<document id="27013400"><sentence text="Hepatocellular Disposition and Transporter Interactions with Tolvaptan and Metabolites in Sandwich-Cultured Human Hepatocytes."><entity charOffset="61-70" id="DDI-PubMed.27013400.s1.e0" text="Tolvaptan" /></sentence><sentence text="Tolvaptan is a selective V2-receptor antagonist primarily metabolized by CYP3A"><entity charOffset="0-9" id="DDI-PubMed.27013400.s2.e0" text="Tolvaptan" /></sentence><sentence text=" The present study investigated the hepatocellular disposition of tolvaptan and the generated tolvaptan metabolites, DM-4103 and DM-4107, as well as the potential for drug-drug interaction (DDIs) with metabolic and transport proteins in sandwich-cultured human hepatocytes (SCHH)"><entity charOffset="66-75" id="DDI-PubMed.27013400.s3.e0" text="tolvaptan" /><entity charOffset="94-103" id="DDI-PubMed.27013400.s3.e1" text="tolvaptan" /><entity charOffset="117-124" id="DDI-PubMed.27013400.s3.e2" text="DM-4103" /><entity charOffset="129-136" id="DDI-PubMed.27013400.s3.e3" text="DM-4107" /><pair ddi="false" e1="DDI-PubMed.27013400.s3.e0" e2="DDI-PubMed.27013400.s3.e0" /><pair ddi="false" e1="DDI-PubMed.27013400.s3.e0" e2="DDI-PubMed.27013400.s3.e1" /><pair ddi="false" e1="DDI-PubMed.27013400.s3.e0" e2="DDI-PubMed.27013400.s3.e2" /><pair ddi="false" e1="DDI-PubMed.27013400.s3.e0" e2="DDI-PubMed.27013400.s3.e3" /><pair ddi="false" e1="DDI-PubMed.27013400.s3.e1" e2="DDI-PubMed.27013400.s3.e1" /><pair ddi="false" e1="DDI-PubMed.27013400.s3.e1" e2="DDI-PubMed.27013400.s3.e2" /><pair ddi="false" e1="DDI-PubMed.27013400.s3.e1" e2="DDI-PubMed.27013400.s3.e3" /><pair ddi="false" e1="DDI-PubMed.27013400.s3.e2" e2="DDI-PubMed.27013400.s3.e2" /><pair ddi="false" e1="DDI-PubMed.27013400.s3.e2" e2="DDI-PubMed.27013400.s3.e3" /></sentence><sentence text=" Tolvaptan was incubated with SCHH and quantified by LC-MS/MS"><entity charOffset="1-10" id="DDI-PubMed.27013400.s4.e0" text="Tolvaptan" /><entity charOffset="30-34" id="DDI-PubMed.27013400.s4.e1" text="SCHH" /><pair ddi="false" e1="DDI-PubMed.27013400.s4.e0" e2="DDI-PubMed.27013400.s4.e0" /><pair ddi="false" e1="DDI-PubMed.27013400.s4.e0" e2="DDI-PubMed.27013400.s4.e1" /></sentence><sentence text=" Pioglitazone, verapamil, MK-571 and elacridar were used as inhibitors to investigate mechanisms of transport and metabolism of tolvaptan and metabolites"><entity charOffset="1-13" id="DDI-PubMed.27013400.s5.e0" text="Pioglitazone" /><entity charOffset="15-24" id="DDI-PubMed.27013400.s5.e1" text="verapamil" /><entity charOffset="26-32" id="DDI-PubMed.27013400.s5.e2" text="MK-571" /><entity charOffset="128-137" id="DDI-PubMed.27013400.s5.e3" text="tolvaptan" /><pair ddi="false" e1="DDI-PubMed.27013400.s5.e0" e2="DDI-PubMed.27013400.s5.e0" /><pair ddi="false" e1="DDI-PubMed.27013400.s5.e0" e2="DDI-PubMed.27013400.s5.e1" /><pair ddi="false" e1="DDI-PubMed.27013400.s5.e0" e2="DDI-PubMed.27013400.s5.e2" /><pair ddi="false" e1="DDI-PubMed.27013400.s5.e0" e2="DDI-PubMed.27013400.s5.e3" /><pair ddi="false" e1="DDI-PubMed.27013400.s5.e1" e2="DDI-PubMed.27013400.s5.e1" /><pair ddi="false" e1="DDI-PubMed.27013400.s5.e1" e2="DDI-PubMed.27013400.s5.e2" /><pair ddi="false" e1="DDI-PubMed.27013400.s5.e1" e2="DDI-PubMed.27013400.s5.e3" /><pair ddi="false" e1="DDI-PubMed.27013400.s5.e2" e2="DDI-PubMed.27013400.s5.e2" /><pair ddi="false" e1="DDI-PubMed.27013400.s5.e2" e2="DDI-PubMed.27013400.s5.e3" /></sentence><sentence text=" Taurocholate (TCA), pravastatin, digoxin, and metformin were used as transporter probes to investigate which transport proteins were inhibited by tolvaptan and metabolites"><entity charOffset="1-13" id="DDI-PubMed.27013400.s6.e0" text="Taurocholate" /><entity charOffset="15-18" id="DDI-PubMed.27013400.s6.e1" text="TCA" /><entity charOffset="21-32" id="DDI-PubMed.27013400.s6.e2" text="pravastatin" /><entity charOffset="34-41" id="DDI-PubMed.27013400.s6.e3" text="digoxin" /><entity charOffset="47-56" id="DDI-PubMed.27013400.s6.e4" text="metformin" /><entity charOffset="147-156" id="DDI-PubMed.27013400.s6.e5" text="tolvaptan" /><pair ddi="false" e1="DDI-PubMed.27013400.s6.e0" e2="DDI-PubMed.27013400.s6.e0" /><pair ddi="false" e1="DDI-PubMed.27013400.s6.e0" e2="DDI-PubMed.27013400.s6.e1" /><pair ddi="false" e1="DDI-PubMed.27013400.s6.e0" e2="DDI-PubMed.27013400.s6.e2" /><pair ddi="false" e1="DDI-PubMed.27013400.s6.e0" e2="DDI-PubMed.27013400.s6.e3" /><pair ddi="false" e1="DDI-PubMed.27013400.s6.e0" e2="DDI-PubMed.27013400.s6.e4" /><pair ddi="false" e1="DDI-PubMed.27013400.s6.e0" e2="DDI-PubMed.27013400.s6.e5" /><pair ddi="false" e1="DDI-PubMed.27013400.s6.e1" e2="DDI-PubMed.27013400.s6.e1" /><pair ddi="false" e1="DDI-PubMed.27013400.s6.e1" e2="DDI-PubMed.27013400.s6.e2" /><pair ddi="false" e1="DDI-PubMed.27013400.s6.e1" e2="DDI-PubMed.27013400.s6.e3" /><pair ddi="false" e1="DDI-PubMed.27013400.s6.e1" e2="DDI-PubMed.27013400.s6.e4" /><pair ddi="false" e1="DDI-PubMed.27013400.s6.e1" e2="DDI-PubMed.27013400.s6.e5" /><pair ddi="false" e1="DDI-PubMed.27013400.s6.e2" e2="DDI-PubMed.27013400.s6.e2" /><pair ddi="false" e1="DDI-PubMed.27013400.s6.e2" e2="DDI-PubMed.27013400.s6.e3" /><pair ddi="false" e1="DDI-PubMed.27013400.s6.e2" e2="DDI-PubMed.27013400.s6.e4" /><pair ddi="false" e1="DDI-PubMed.27013400.s6.e2" e2="DDI-PubMed.27013400.s6.e5" /><pair ddi="false" e1="DDI-PubMed.27013400.s6.e3" e2="DDI-PubMed.27013400.s6.e3" /><pair ddi="false" e1="DDI-PubMed.27013400.s6.e3" e2="DDI-PubMed.27013400.s6.e4" /><pair ddi="false" e1="DDI-PubMed.27013400.s6.e3" e2="DDI-PubMed.27013400.s6.e5" /><pair ddi="false" e1="DDI-PubMed.27013400.s6.e4" e2="DDI-PubMed.27013400.s6.e4" /><pair ddi="false" e1="DDI-PubMed.27013400.s6.e4" e2="DDI-PubMed.27013400.s6.e5" /></sentence><sentence text=" Cellular accumulation of tolvaptan (0"><entity charOffset="26-35" id="DDI-PubMed.27013400.s7.e0" text="tolvaptan" /></sentence><sentence text="15-50 μM), DM-4103 and DM-4107 in SCHH was concentration dependent"><entity charOffset="34-38" id="DDI-PubMed.27013400.s8.e0" text="SCHH" /></sentence><sentence text=" Tolvaptan accumulation (15 μM) in SCHH was not altered markedly by 50 μM pioglitazone, verapamil or MK-571, or 10 μM elacridar"><entity charOffset="1-10" id="DDI-PubMed.27013400.s9.e0" text="Tolvaptan" /><entity charOffset="74-86" id="DDI-PubMed.27013400.s9.e1" text="pioglitazone" /><entity charOffset="88-97" id="DDI-PubMed.27013400.s9.e2" text="verapamil" /><entity charOffset="101-107" id="DDI-PubMed.27013400.s9.e3" text="MK-571" /><entity charOffset="35-40" id="DDI-PubMed.27013400.s9.e4" text="SCHH" /><pair ddi="false" e1="DDI-PubMed.27013400.s9.e0" e2="DDI-PubMed.27013400.s9.e0" /><pair ddi="false" e1="DDI-PubMed.27013400.s9.e0" e2="DDI-PubMed.27013400.s9.e4" /><pair ddi="false" e1="DDI-PubMed.27013400.s9.e0" e2="DDI-PubMed.27013400.s9.e1" /><pair ddi="false" e1="DDI-PubMed.27013400.s9.e0" e2="DDI-PubMed.27013400.s9.e2" /><pair ddi="false" e1="DDI-PubMed.27013400.s9.e0" e2="DDI-PubMed.27013400.s9.e3" /><pair ddi="false" e1="DDI-PubMed.27013400.s9.e4" e2="DDI-PubMed.27013400.s9.e4" /><pair ddi="false" e1="DDI-PubMed.27013400.s9.e4" e2="DDI-PubMed.27013400.s9.e1" /><pair ddi="false" e1="DDI-PubMed.27013400.s9.e4" e2="DDI-PubMed.27013400.s9.e2" /><pair ddi="false" e1="DDI-PubMed.27013400.s9.e4" e2="DDI-PubMed.27013400.s9.e3" /><pair ddi="false" e1="DDI-PubMed.27013400.s9.e1" e2="DDI-PubMed.27013400.s9.e1" /><pair ddi="false" e1="DDI-PubMed.27013400.s9.e1" e2="DDI-PubMed.27013400.s9.e2" /><pair ddi="false" e1="DDI-PubMed.27013400.s9.e1" e2="DDI-PubMed.27013400.s9.e3" /><pair ddi="false" e1="DDI-PubMed.27013400.s9.e2" e2="DDI-PubMed.27013400.s9.e2" /><pair ddi="false" e1="DDI-PubMed.27013400.s9.e2" e2="DDI-PubMed.27013400.s9.e3" /></sentence><sentence text=" Co-incubation of tolvaptan with pioglitazone, verapamil, MK-571 and elacridar reduced DM-4107 accumulation by 45"><entity charOffset="18-27" id="DDI-PubMed.27013400.s10.e0" text="tolvaptan" /><entity charOffset="33-45" id="DDI-PubMed.27013400.s10.e1" text="pioglitazone" /><entity charOffset="47-56" id="DDI-PubMed.27013400.s10.e2" text="verapamil" /><entity charOffset="58-64" id="DDI-PubMed.27013400.s10.e3" text="MK-571" /><entity charOffset="87-94" id="DDI-PubMed.27013400.s10.e4" text="DM-4107" /><pair ddi="false" e1="DDI-PubMed.27013400.s10.e0" e2="DDI-PubMed.27013400.s10.e0" /><pair ddi="false" e1="DDI-PubMed.27013400.s10.e0" e2="DDI-PubMed.27013400.s10.e1" /><pair ddi="false" e1="DDI-PubMed.27013400.s10.e0" e2="DDI-PubMed.27013400.s10.e2" /><pair ddi="false" e1="DDI-PubMed.27013400.s10.e0" e2="DDI-PubMed.27013400.s10.e3" /><pair ddi="false" e1="DDI-PubMed.27013400.s10.e0" e2="DDI-PubMed.27013400.s10.e4" /><pair ddi="false" e1="DDI-PubMed.27013400.s10.e1" e2="DDI-PubMed.27013400.s10.e1" /><pair ddi="false" e1="DDI-PubMed.27013400.s10.e1" e2="DDI-PubMed.27013400.s10.e2" /><pair ddi="false" e1="DDI-PubMed.27013400.s10.e1" e2="DDI-PubMed.27013400.s10.e3" /><pair ddi="false" e1="DDI-PubMed.27013400.s10.e1" e2="DDI-PubMed.27013400.s10.e4" /><pair ddi="false" e1="DDI-PubMed.27013400.s10.e2" e2="DDI-PubMed.27013400.s10.e2" /><pair ddi="false" e1="DDI-PubMed.27013400.s10.e2" e2="DDI-PubMed.27013400.s10.e3" /><pair ddi="false" e1="DDI-PubMed.27013400.s10.e2" e2="DDI-PubMed.27013400.s10.e4" /><pair ddi="false" e1="DDI-PubMed.27013400.s10.e3" e2="DDI-PubMed.27013400.s10.e3" /><pair ddi="false" e1="DDI-PubMed.27013400.s10.e3" e2="DDI-PubMed.27013400.s10.e4" /></sentence><sentence text="6, 79" /><sentence text="8, 94" /><sentence text="5 and 23" /><sentence text="0%, respectively, relative to control" /><sentence text=" Co-incubation with increasing tolvaptan concentrations (0"><entity charOffset="31-40" id="DDI-PubMed.27013400.s15.e0" text="tolvaptan" /></sentence><sentence text="15-50 μM) decreased TCA (2"><entity charOffset="20-28" id="DDI-PubMed.27013400.s16.e0" text="TCA" /></sentence><sentence text="5 μM) cell+bile accumulation and the TCA biliary excretion index (BEI; from 76% to 51%), consistent with inhibition of the bile salt export pump (BSEP)"><entity charOffset="37-39" id="DDI-PubMed.27013400.s17.e0" text="TCA" /></sentence><sentence text=" Tolvaptan (15 μM) had no effect on the cellular accumulation of 2"><entity charOffset="1-10" id="DDI-PubMed.27013400.s18.e0" text="Tolvaptan" /></sentence><sentence text="5 μM pravastatin or metformin"><entity charOffset="0-16" id="DDI-PubMed.27013400.s19.e0" text="5 μM pravastatin" /><entity charOffset="20-29" id="DDI-PubMed.27013400.s19.e1" text="metformin" /><pair ddi="false" e1="DDI-PubMed.27013400.s19.e0" e2="DDI-PubMed.27013400.s19.e0" /><pair ddi="false" e1="DDI-PubMed.27013400.s19.e0" e2="DDI-PubMed.27013400.s19.e1" /></sentence><sentence text=" Digoxin cellular accumulation increased and the BEI of digoxin decreased from 23"><entity charOffset="1-8" id="DDI-PubMed.27013400.s20.e0" text="Digoxin" /><entity charOffset="56-63" id="DDI-PubMed.27013400.s20.e1" text="digoxin" /><pair ddi="false" e1="DDI-PubMed.27013400.s20.e0" e2="DDI-PubMed.27013400.s20.e0" /><pair ddi="false" e1="DDI-PubMed.27013400.s20.e0" e2="DDI-PubMed.27013400.s20.e1" /></sentence><sentence text="9% to 8" /><sentence text="1% in the presence of 15 μM tolvaptan, consistent with inhibition of P-glycoprotein (P-gp)"><entity charOffset="28-37" id="DDI-PubMed.27013400.s22.e0" text="tolvaptan" /></sentence><sentence text=" In summary, SCHH studies revealed potential metabolic- and transporter-mediated DDIs involving tolvaptan and metabolites"><entity charOffset="13-17" id="DDI-PubMed.27013400.s23.e0" text="SCHH" /><entity charOffset="96-105" id="DDI-PubMed.27013400.s23.e1" text="tolvaptan" /><pair ddi="false" e1="DDI-PubMed.27013400.s23.e0" e2="DDI-PubMed.27013400.s23.e0" /><pair ddi="false" e1="DDI-PubMed.27013400.s23.e0" e2="DDI-PubMed.27013400.s23.e1" /></sentence><sentence text="" /></document>